demand for the product;
-- changes in prescribing or procedural practices of infectious disease,
gastroenterology and internal medicine doctors, including off-label
prescribing of other products;
-- actions by the FDA, the Internal Revenue Service or other government
-- decreases in the rate of infections for which Vancocin is prescribed;
-- decrease in the sensitivity of the relevant bacteria to Vancocin;
-- changes in terms required by wholesalers, including fee-for-service
-- the timing and results of anticipated events in the Company's CMV, NTCD
and HCV programs; and
-- the timing and nature of potential business development activities
related to the Company's efforts to expand its current portfolio
through in-licensing or other means of acquiring products in clinical
development or marketed products.
There can be no assurance that NTCD will one day be the therapy of
choice for recurrent CDI, that recurrence of CDI will remain a significant
medical need in CDI patients, that ViroPharma will conduct additional HCV
studies in the future, that FDA or EMEA will not require additional or
unanticipated studies or clinical trial outcomes before granting regulatory
approval of any of its product candidates, or that ViroPharma will be
successful in gaining regulatory approval of any of its product candidates.
These factors, and other factors, including, but not limited to those
described in ViroPharma's quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission during 2007, could cause future results
to differ materially from the expectations expressed in this press release.
The forward-looking statements contained in this press release may become
outdated over time. ViroPharma does not assume any responsibility for
updating any forward-looking statements.
|SOURCE ViroPharma Incorporated|
Copyright©2008 PR Newswire.
All rights reserved